Global Prostate Cancer Nuclear Medicine Diagnostics Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Prostate Cancer Nuclear Medicine Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Prostate Cancer Nuclear Medicine Diagnostics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Prostate Cancer Nuclear Medicine Diagnostics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While SPECT segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Prostate Cancer Nuclear Medicine Diagnostics include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, and Jubilant Pharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Prostate Cancer Nuclear Medicine Diagnostics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Prostate Cancer Nuclear Medicine Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Prostate Cancer Nuclear Medicine Diagnostics, with revenue, gross margin and global market share of Prostate Cancer Nuclear Medicine Diagnostics from 2019 to 2022.
Chapter 3, the Prostate Cancer Nuclear Medicine Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Prostate Cancer Nuclear Medicine Diagnostics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Prostate Cancer Nuclear Medicine Diagnostics research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Prostate Cancer Nuclear Medicine Diagnostics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Prostate Cancer Nuclear Medicine Diagnostics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While SPECT segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Prostate Cancer Nuclear Medicine Diagnostics include Blue Earth Diagnostics, PETNET Solutions, Cardinal Health, Lantheus Medical Imaging, and Jubilant Pharma, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Prostate Cancer Nuclear Medicine Diagnostics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- SPECT
- PET
- Hospitals
- Clinics
- Others
- Blue Earth Diagnostics
- PETNET Solutions
- Cardinal Health
- Lantheus Medical Imaging
- Jubilant Pharma
- NCM-USA
- Progenics Pharma
- Telix Pharma
- ImaginAb
- Theragnostics
- Novartis
- Alliance Medical
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Prostate Cancer Nuclear Medicine Diagnostics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Prostate Cancer Nuclear Medicine Diagnostics, with revenue, gross margin and global market share of Prostate Cancer Nuclear Medicine Diagnostics from 2019 to 2022.
Chapter 3, the Prostate Cancer Nuclear Medicine Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Prostate Cancer Nuclear Medicine Diagnostics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Prostate Cancer Nuclear Medicine Diagnostics research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Prostate Cancer Nuclear Medicine Diagnostics
1.2 Classification of Prostate Cancer Nuclear Medicine Diagnostics by Type
1.2.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type in 2021
1.2.3 SPECT
1.2.4 PET
1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market by Application
1.3.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size & Forecast
1.5 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast by Region
1.5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region, (2017-2022)
1.5.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.6 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
1.6.2 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
1.6.3 Prostate Cancer Nuclear Medicine Diagnostics Trends Analysis
2 COMPANY PROFILES
2.1 Blue Earth Diagnostics
2.1.1 Blue Earth Diagnostics Details
2.1.2 Blue Earth Diagnostics Major Business
2.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Blue Earth Diagnostics Recent Developments and Future Plans
2.2 PETNET Solutions
2.2.1 PETNET Solutions Details
2.2.2 PETNET Solutions Major Business
2.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 PETNET Solutions Recent Developments and Future Plans
2.3 Cardinal Health
2.3.1 Cardinal Health Details
2.3.2 Cardinal Health Major Business
2.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Cardinal Health Recent Developments and Future Plans
2.4 Lantheus Medical Imaging
2.4.1 Lantheus Medical Imaging Details
2.4.2 Lantheus Medical Imaging Major Business
2.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Lantheus Medical Imaging Recent Developments and Future Plans
2.5 Jubilant Pharma
2.5.1 Jubilant Pharma Details
2.5.2 Jubilant Pharma Major Business
2.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Jubilant Pharma Recent Developments and Future Plans
2.6 NCM-USA
2.6.1 NCM-USA Details
2.6.2 NCM-USA Major Business
2.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 NCM-USA Recent Developments and Future Plans
2.7 Progenics Pharma
2.7.1 Progenics Pharma Details
2.7.2 Progenics Pharma Major Business
2.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Progenics Pharma Recent Developments and Future Plans
2.8 Telix Pharma
2.8.1 Telix Pharma Details
2.8.2 Telix Pharma Major Business
2.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Telix Pharma Recent Developments and Future Plans
2.9 ImaginAb
2.9.1 ImaginAb Details
2.9.2 ImaginAb Major Business
2.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 ImaginAb Recent Developments and Future Plans
2.10 Theragnostics
2.10.1 Theragnostics Details
2.10.2 Theragnostics Major Business
2.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Theragnostics Recent Developments and Future Plans
2.11 Novartis
2.11.1 Novartis Details
2.11.2 Novartis Major Business
2.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Novartis Recent Developments and Future Plans
2.12 Alliance Medical
2.12.1 Alliance Medical Details
2.12.2 Alliance Medical Major Business
2.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Alliance Medical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share in 2021
3.2.2 Top 10 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Prostate Cancer Nuclear Medicine Diagnostics Players Head Office, Products and Services Provided
3.4 Prostate Cancer Nuclear Medicine Diagnostics Mergers & Acquisitions
3.5 Prostate Cancer Nuclear Medicine Diagnostics New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Market Share by Type (2017-2022)
4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2017-2022)
5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
6.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
6.3.2 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
7.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
7.3.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.5 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.6 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region
8.3.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2017-2028)
8.3.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.5 India Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.7 Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
9.2 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
9.3 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
9.3.1 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
9.3.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
9.3.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
10.3.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
10.3.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
10.3.4 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Product Overview and Scope of Prostate Cancer Nuclear Medicine Diagnostics
1.2 Classification of Prostate Cancer Nuclear Medicine Diagnostics by Type
1.2.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type in 2021
1.2.3 SPECT
1.2.4 PET
1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market by Application
1.3.1 Overview: Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size & Forecast
1.5 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast by Region
1.5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region, (2017-2022)
1.5.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.6 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
1.6.2 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
1.6.3 Prostate Cancer Nuclear Medicine Diagnostics Trends Analysis
2 COMPANY PROFILES
2.1 Blue Earth Diagnostics
2.1.1 Blue Earth Diagnostics Details
2.1.2 Blue Earth Diagnostics Major Business
2.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.1.4 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Blue Earth Diagnostics Recent Developments and Future Plans
2.2 PETNET Solutions
2.2.1 PETNET Solutions Details
2.2.2 PETNET Solutions Major Business
2.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.2.4 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 PETNET Solutions Recent Developments and Future Plans
2.3 Cardinal Health
2.3.1 Cardinal Health Details
2.3.2 Cardinal Health Major Business
2.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.3.4 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Cardinal Health Recent Developments and Future Plans
2.4 Lantheus Medical Imaging
2.4.1 Lantheus Medical Imaging Details
2.4.2 Lantheus Medical Imaging Major Business
2.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.4.4 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Lantheus Medical Imaging Recent Developments and Future Plans
2.5 Jubilant Pharma
2.5.1 Jubilant Pharma Details
2.5.2 Jubilant Pharma Major Business
2.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.5.4 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Jubilant Pharma Recent Developments and Future Plans
2.6 NCM-USA
2.6.1 NCM-USA Details
2.6.2 NCM-USA Major Business
2.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.6.4 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 NCM-USA Recent Developments and Future Plans
2.7 Progenics Pharma
2.7.1 Progenics Pharma Details
2.7.2 Progenics Pharma Major Business
2.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.7.4 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Progenics Pharma Recent Developments and Future Plans
2.8 Telix Pharma
2.8.1 Telix Pharma Details
2.8.2 Telix Pharma Major Business
2.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.8.4 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Telix Pharma Recent Developments and Future Plans
2.9 ImaginAb
2.9.1 ImaginAb Details
2.9.2 ImaginAb Major Business
2.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.9.4 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 ImaginAb Recent Developments and Future Plans
2.10 Theragnostics
2.10.1 Theragnostics Details
2.10.2 Theragnostics Major Business
2.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.10.4 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Theragnostics Recent Developments and Future Plans
2.11 Novartis
2.11.1 Novartis Details
2.11.2 Novartis Major Business
2.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.11.4 Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Novartis Recent Developments and Future Plans
2.12 Alliance Medical
2.12.1 Alliance Medical Details
2.12.2 Alliance Medical Major Business
2.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
2.12.4 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Alliance Medical Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share in 2021
3.2.2 Top 10 Prostate Cancer Nuclear Medicine Diagnostics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Prostate Cancer Nuclear Medicine Diagnostics Players Head Office, Products and Services Provided
3.4 Prostate Cancer Nuclear Medicine Diagnostics Mergers & Acquisitions
3.5 Prostate Cancer Nuclear Medicine Diagnostics New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Market Share by Type (2017-2022)
4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application (2017-2022)
5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
6.2 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
6.3.1 North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
6.3.2 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
6.3.3 Canada Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
6.3.4 Mexico Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
7.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
7.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
7.3.2 Germany Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.3 France Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.5 Russia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
7.3.6 Italy Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
8.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
8.3 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region
8.3.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2017-2028)
8.3.2 China Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.4 South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.5 India Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
8.3.7 Australia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
9.2 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
9.3 South America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
9.3.1 South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
9.3.2 Brazil Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
9.3.3 Argentina Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2028)
10.2 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2028)
10.3 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size by Country
10.3.1 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2028)
10.3.2 Turkey Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
10.3.4 UAE Prostate Cancer Nuclear Medicine Diagnostics Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Prostate Cancer Nuclear Medicine Diagnostics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2023-2028)
Table 6. Blue Earth Diagnostics Corporate Information, Head Office, and Major Competitors
Table 7. Blue Earth Diagnostics Major Business
Table 8. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 9. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. PETNET Solutions Corporate Information, Head Office, and Major Competitors
Table 11. PETNET Solutions Major Business
Table 12. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 13. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Cardinal Health Corporate Information, Head Office, and Major Competitors
Table 15. Cardinal Health Major Business
Table 16. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 17. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Lantheus Medical Imaging Corporate Information, Head Office, and Major Competitors
Table 19. Lantheus Medical Imaging Major Business
Table 20. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 21. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Jubilant Pharma Corporate Information, Head Office, and Major Competitors
Table 23. Jubilant Pharma Major Business
Table 24. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 25. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. NCM-USA Corporate Information, Head Office, and Major Competitors
Table 27. NCM-USA Major Business
Table 28. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 29. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Progenics Pharma Corporate Information, Head Office, and Major Competitors
Table 31. Progenics Pharma Major Business
Table 32. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 33. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Telix Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Telix Pharma Major Business
Table 36. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 37. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. ImaginAb Corporate Information, Head Office, and Major Competitors
Table 39. ImaginAb Major Business
Table 40. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 41. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Theragnostics Corporate Information, Head Office, and Major Competitors
Table 43. Theragnostics Major Business
Table 44. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 45. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Novartis Corporate Information, Head Office, and Major Competitors
Table 47. Novartis Major Business
Table 48. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 49. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Alliance Medical Corporate Information, Head Office, and Major Competitors
Table 51. Alliance Medical Major Business
Table 52. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 53. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 55. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 56. Breakdown of Prostate Cancer Nuclear Medicine Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Prostate Cancer Nuclear Medicine Diagnostics Players Head Office, Products and Services Provided
Table 58. Prostate Cancer Nuclear Medicine Diagnostics Mergers & Acquisitions in the Past Five Years
Table 59. Prostate Cancer Nuclear Medicine Diagnostics New Entrants and Expansion Plans
Table 60. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Type (2017-2022)
Table 61. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Type (2017-2022)
Table 62. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Forecast by Type (2023-2028)
Table 63. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022)
Table 64. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Forecast by Application (2023-2028)
Table 65. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 66. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 67. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 68. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 69. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 70. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 71. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 72. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 73. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 74. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 75. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 76. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 77. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 78. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 79. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 80. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 81. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2017-2022) & (USD Million)
Table 82. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2023-2028) & (USD Million)
Table 83. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 84. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 85. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 86. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 87. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 88. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 89. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 90. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 91. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 92. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 93. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 94. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 1. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Prostate Cancer Nuclear Medicine Diagnostics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2023-2028)
Table 6. Blue Earth Diagnostics Corporate Information, Head Office, and Major Competitors
Table 7. Blue Earth Diagnostics Major Business
Table 8. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 9. Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. PETNET Solutions Corporate Information, Head Office, and Major Competitors
Table 11. PETNET Solutions Major Business
Table 12. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 13. PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Cardinal Health Corporate Information, Head Office, and Major Competitors
Table 15. Cardinal Health Major Business
Table 16. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 17. Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Lantheus Medical Imaging Corporate Information, Head Office, and Major Competitors
Table 19. Lantheus Medical Imaging Major Business
Table 20. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 21. Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Jubilant Pharma Corporate Information, Head Office, and Major Competitors
Table 23. Jubilant Pharma Major Business
Table 24. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 25. Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. NCM-USA Corporate Information, Head Office, and Major Competitors
Table 27. NCM-USA Major Business
Table 28. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 29. NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Progenics Pharma Corporate Information, Head Office, and Major Competitors
Table 31. Progenics Pharma Major Business
Table 32. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 33. Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Telix Pharma Corporate Information, Head Office, and Major Competitors
Table 35. Telix Pharma Major Business
Table 36. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 37. Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. ImaginAb Corporate Information, Head Office, and Major Competitors
Table 39. ImaginAb Major Business
Table 40. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 41. ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Theragnostics Corporate Information, Head Office, and Major Competitors
Table 43. Theragnostics Major Business
Table 44. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 45. Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Novartis Corporate Information, Head Office, and Major Competitors
Table 47. Novartis Major Business
Table 48. Novartis Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 49. Novartis Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Alliance Medical Corporate Information, Head Office, and Major Competitors
Table 51. Alliance Medical Major Business
Table 52. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Product and Solutions
Table 53. Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 55. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 56. Breakdown of Prostate Cancer Nuclear Medicine Diagnostics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Prostate Cancer Nuclear Medicine Diagnostics Players Head Office, Products and Services Provided
Table 58. Prostate Cancer Nuclear Medicine Diagnostics Mergers & Acquisitions in the Past Five Years
Table 59. Prostate Cancer Nuclear Medicine Diagnostics New Entrants and Expansion Plans
Table 60. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) by Type (2017-2022)
Table 61. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Type (2017-2022)
Table 62. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Forecast by Type (2023-2028)
Table 63. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022)
Table 64. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Forecast by Application (2023-2028)
Table 65. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 66. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 67. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 68. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 69. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 70. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 71. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 72. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 73. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 74. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 75. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 76. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 77. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 78. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 79. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 80. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 81. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2017-2022) & (USD Million)
Table 82. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue by Region (2023-2028) & (USD Million)
Table 83. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 84. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 85. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 86. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 87. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 88. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
Table 89. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2017-2022) & (USD Million)
Table 90. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Type (2023-2028) & (USD Million)
Table 91. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2017-2022) & (USD Million)
Table 92. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Application (2023-2028) & (USD Million)
Table 93. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2017-2022) & (USD Million)
Table 94. Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue by Country (2023-2028) & (USD Million)
LIST OF FIGURES
Figure 1. Prostate Cancer Nuclear Medicine Diagnostics Picture
Figure 2. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type in 2021
Figure 3. SPECT
Figure 4. PET
Figure 5. Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application in 2021
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2017-2028)
Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region in 2021
Figure 13. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
Figure 19. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
Figure 20. Prostate Cancer Nuclear Medicine Diagnostics Market Trends
Figure 21. Blue Earth Diagnostics Recent Developments and Future Plans
Figure 22. PETNET Solutions Recent Developments and Future Plans
Figure 23. Cardinal Health Recent Developments and Future Plans
Figure 24. Lantheus Medical Imaging Recent Developments and Future Plans
Figure 25. Jubilant Pharma Recent Developments and Future Plans
Figure 26. NCM-USA Recent Developments and Future Plans
Figure 27. Progenics Pharma Recent Developments and Future Plans
Figure 28. Telix Pharma Recent Developments and Future Plans
Figure 29. ImaginAb Recent Developments and Future Plans
Figure 30. Theragnostics Recent Developments and Future Plans
Figure 31. Novartis Recent Developments and Future Plans
Figure 32. Alliance Medical Recent Developments and Future Plans
Figure 33. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Players in 2021
Figure 34. Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share in 2021
Figure 36. Global Top 10 Players Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Type in 2021
Figure 39. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Type (2023-2028)
Figure 40. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Application in 2021
Figure 41. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Application (2023-2028)
Figure 42. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 43. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 44. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 45. United States Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 49. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 50. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 51. Germany Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2017-2028)
Figure 59. China Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 66. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 67. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
Figure 1. Prostate Cancer Nuclear Medicine Diagnostics Picture
Figure 2. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Type in 2021
Figure 3. SPECT
Figure 4. PET
Figure 5. Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Application in 2021
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2017-2028)
Figure 12. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region in 2021
Figure 13. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
Figure 19. Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
Figure 20. Prostate Cancer Nuclear Medicine Diagnostics Market Trends
Figure 21. Blue Earth Diagnostics Recent Developments and Future Plans
Figure 22. PETNET Solutions Recent Developments and Future Plans
Figure 23. Cardinal Health Recent Developments and Future Plans
Figure 24. Lantheus Medical Imaging Recent Developments and Future Plans
Figure 25. Jubilant Pharma Recent Developments and Future Plans
Figure 26. NCM-USA Recent Developments and Future Plans
Figure 27. Progenics Pharma Recent Developments and Future Plans
Figure 28. Telix Pharma Recent Developments and Future Plans
Figure 29. ImaginAb Recent Developments and Future Plans
Figure 30. Theragnostics Recent Developments and Future Plans
Figure 31. Novartis Recent Developments and Future Plans
Figure 32. Alliance Medical Recent Developments and Future Plans
Figure 33. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Players in 2021
Figure 34. Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 35. Global Top 3 Players Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share in 2021
Figure 36. Global Top 10 Players Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share in 2021
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 38. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Type in 2021
Figure 39. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Type (2023-2028)
Figure 40. Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Share by Application in 2021
Figure 41. Global Prostate Cancer Nuclear Medicine Diagnostics Market Share Forecast by Application (2023-2028)
Figure 42. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 43. North America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 44. North America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 45. United States Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 46. Canada Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Mexico Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 49. Europe Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 50. Europe Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 51. Germany Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. France Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. United Kingdom Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Russia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Italy Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 57. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 58. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Region (2017-2028)
Figure 59. China Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Japan Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South Korea Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. India Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Australia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 66. South America Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 67. South America Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Type (2017-2028)
Figure 71. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Sales Market Share by Application (2017-2028)
Figure 72. Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Country (2017-2028)
Figure 73. Turkey Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. UAE Prostate Cancer Nuclear Medicine Diagnostics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
